You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Biofuel Production from Grease Trap Waste

    SBC: Environmental Fuel Research, LLC            Topic: F

    Environmental Fuel Research, LLC, proposes to commercialize a grease trap waste to biofuel process based on process research from Drexel University. Grease trap waste is dirty and low-value material produced by the food service industry that is high in lipids that can be converted to biodiesel. The quantity of grease trap waste in the United States could produce one-half billion gallons of biodies ...

    SBIR Phase I 2014 Environmental Protection Agency
  2. Low-Cost, Regenerable Air Filter for Efficient Gaseous Pollutants Removal

    SBC: PRECISION COMBUSTION, INC.            Topic: D

    Precision Combustion, Inc. (PCI) proposes to develop a regenerable, low-cost, high-efficiency pollution control technology for removal of gaseous pollutants from contaminated air streams. This innovative air filter technology will combine our novel proprietary Microlith® support elements with sorbent nanomaterials that can be tailored to capture a variety of targeted gaseous pollutants. Originall ...

    SBIR Phase I 2014 Environmental Protection Agency
  3. Targeted Inactivation of the CCR5 HIV Coreceptor with Peptide Nucleic Acids

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Over 34 million people are currently living with HIV/AIDS. Combination antiviral therapies have significantly reduced the morbidity and mortality of the disease; however, there is currently no cure for the disease. Discovery that a naturally occurring variant of CCR5, the delta32 mutation, renders cells resistant to HIV infection has led to efforts by several a ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Local Lymph Node Assay with IL-18 Endpoints

    SBC: MB RESEARCH LABORATORIES, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The current industry standard for predicting contact dermal sensitization is the murine Local Lymph Node Assay (LLNA). A significant limitation of the LLNA is the frequency of false positives, as well as the occurrenceof false negatives. This limitation occurs as a result of the LLNA inability to always correctly distinguish between substances that are strongly ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Formulation of LbL microparticle vaccine in microneedle array for intradermal del

    SBC: ARTIFICIAL CELL TECHNOLOGIES INC            Topic: NIAID

    Abstract The ability of the immune system to recognize and initiate an immune response to foreign particles such as bacteria and viruses has generated interest in development of particulate vaccine technologies. We are developing an innovative approach toproduce particulate vaccines via layer-by-layer (LbL) fabrication of synthetic microparticles (MP). We have shown that LbL-MP loaded with epitope ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Ubiquitin pathway inhibitors for treatment of asthma

    SBC: Progenra, Inc            Topic: NIAID

    DESCRIPTION (provided by applicant): Asthma is a chronic disease with considerable morbidity and no cures. Symptomatic treatment is efficacious but produces significant adverse effects. Thus, improved, targeted therapies for asthma are needed. Asthma develops when T cells (CD4+) differentiate to effector T cells, which secrete cytokines that assist in the recruitment and proliferation of various i ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Host-Targeted Mechanism of Action for Treatment of Seasonal and Pandemic Influenz

    SBC: EVRYS BIO LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Despite improvements in vaccine design, manufacture, and distribution, influenza A infection remains a significant public health concern. The February 2013 CDC Interim Adjusted Estimates of Seasonal Influenza Vaccine Effectiveness reported overall vaccine effectiveness of 56% and 67% against influenza A and B infections, respectively, with much reduced effect ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. A New Generation of Botulinum Toxin Vaccines

    SBC: INVENTOX INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Botulinum toxin is one of the six categories of pathogens that have been designated as Category A Select Agents by the Centers for Disease Control. The toxin, which is generally acknowledged to be the most potent biological poison known, enters the body and acts on peripheral cholinergic nerve endings to cause paralysis of transmission. In seriously poisoned pa ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. A Single Antiviral to Treat Multiple Opportunistic Infections

    SBC: EVRYS BIO LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Transplant patients are quite susceptible to opportunistic viral infection resulting from immune suppression necessary for maintenance of their graft. In the case of renal transplant, 17,604 patients in 2011, a new graft means being taken off dialysis, improving quality of life and saving U.S. healthcare nearly 1 B annually. Therefore it is essential that the ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Novel bispecific T cell engaging antibodies for treatment of Lyme disease

    SBC: ABZYME THERAPEUTICS LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Lyme disease (LD) is the most commonly reported tick-borne illness in the United States. According to the recent Center for Disease Control and Prevention report, approximately 300,000 Lyme cases are diagnosed each year. If left untreated, the infection spreads to joints, the heart and the nervous system. In most cases, infections and associated symptoms are el ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government